Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1978 1
1997 1
1999 3
2000 1
2003 2
2004 1
2005 2
2006 6
2007 7
2008 3
2009 1
2010 4
2011 1
2012 5
2013 3
2014 3
2015 5
2017 2
2018 1
2019 3
2021 1
2022 6
2023 3
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

60 results

Results by year

Filters applied: . Clear all
Quoted phrase not found in phrase index: "Bisphosphonate - Induced Nephropathy"
Page 1
Hypocalcemia Risk of Denosumab Across the Spectrum of Kidney Disease: A Population-Based Cohort Study.
Cowan A, Jeyakumar N, McArthur E, Fleet JL, Kanagalingam T, Karp I, Khan T, Muanda FT, Nash DM, Silver SA, Thain J, Weir MA, Garg AX, Clemens KK. Cowan A, et al. J Bone Miner Res. 2023 May;38(5):650-658. doi: 10.1002/jbmr.4804. Epub 2023 Apr 9. J Bone Miner Res. 2023. PMID: 36970786 Free article.
Denosumab can be used in patients with chronic kidney disease (CKD) but has been linked with cases of severe hypocalcemia. ...In those with an eGFR <15 or receiving maintenance dialysis, the incidence of mild and severe hypocalcemia was 24.1% (95% CI 18.1, 30.7) and 14. …
Denosumab can be used in patients with chronic kidney disease (CKD) but has been linked with cases of severe hypocalcemia. ...In thos …
Efficacy and safety of medications for osteoporosis in kidney transplant recipients or patients with chronic kidney disease: A meta-analysis.
Leng Y, Yu X, Yang Y, Xia Y. Leng Y, et al. J Investig Med. 2023 Oct;71(7):760-772. doi: 10.1177/10815589231184215. Epub 2023 Jun 30. J Investig Med. 2023. PMID: 37387531 Review.
This study conducted a meta-analysis to analyze the efficacy and safety of osteoporosis medications in kidney transplant recipients and patients with chronic kidney disease (CKD). ...We performed a meta-analysis of the efficacy and safety of osteoporosis medications …
This study conducted a meta-analysis to analyze the efficacy and safety of osteoporosis medications in kidney transplant recipients a …
Bisphosphonate drug holidays--when, why and for how long?
Anagnostis P, Stevenson JC. Anagnostis P, et al. Climacteric. 2015;18 Suppl 2:32-8. doi: 10.3109/13697137.2015.1099092. Epub 2015 Oct 27. Climacteric. 2015. PMID: 26507608 Review.
Bisphosphonates are first-line agents used for the treatment of osteoporosis in postmenopausal women and men. ...In this respect, the concept of a 'drug holiday' after completion of a reasonable period of bisphosphonate therapy has emerged. Theoretically, this allow …
Bisphosphonates are first-line agents used for the treatment of osteoporosis in postmenopausal women and men. ...In this respect, the …
The safety of zoledronic acid.
Lipton A. Lipton A. Expert Opin Drug Saf. 2007 May;6(3):305-13. doi: 10.1517/14740338.6.3.305. Expert Opin Drug Saf. 2007. PMID: 17480179 Review.
The safety profile of zoledronic acid in this patient population is well established from the databases of several large, randomized, Phase III trials and postmarketing clinical experience. Zoledronic acid is well tolerated, with predictable side effects, primarily transie …
The safety profile of zoledronic acid in this patient population is well established from the databases of several large, randomized, Phase …
Renal complications from bisphosphonate treatment.
Hirschberg R. Hirschberg R. Curr Opin Support Palliat Care. 2012 Sep;6(3):342-7. doi: 10.1097/SPC.0b013e328356062e. Curr Opin Support Palliat Care. 2012. PMID: 22710581 Review.
PURPOSE OF REVIEW: More than 10 years ago evidence emerged that bisphosphonate therapy especially in malignant bone diseases is associated with renal complications. ...SUMMARY: Renal complications with bisphosphonates are rare but creatinine monitoring, espec …
PURPOSE OF REVIEW: More than 10 years ago evidence emerged that bisphosphonate therapy especially in malignant bone diseases i …
Targeted microbubbles: a novel application for the treatment of kidney stones.
Ramaswamy K, Marx V, Laser D, Kenny T, Chi T, Bailey M, Sorensen MD, Grubbs RH, Stoller ML. Ramaswamy K, et al. BJU Int. 2015 Jul;116(1):9-16. doi: 10.1111/bju.12996. Epub 2015 Mar 17. BJU Int. 2015. PMID: 25402588 Free PMC article. Review.
The shockwaves induced the formation of cavitation bubbles, whose collapse released energy at the stone, and the energy fragmented the kidney stones into pieces small enough to be passed spontaneously. ...Two important observations have been established: (i) …
The shockwaves induced the formation of cavitation bubbles, whose collapse released energy at the stone, and the energy fragmented th …
Bisphosphonate use and risk of renal cell carcinoma: A population-based case-control study.
Chung BI, Hellfritzsch M, Ulrichsen SP, Sørensen HT, Ehrenstein V. Chung BI, et al. Basic Clin Pharmacol Toxicol. 2019 May;124(5):642-646. doi: 10.1111/bcpt.13180. Epub 2019 Jan 4. Basic Clin Pharmacol Toxicol. 2019. PMID: 30472809 Free article.
The purpose of this study was to evaluate the association between the use of bisphosphonates and the risk of developing renal cell carcinoma (RCC). ...Smoking could not be directly controlled for in the analysis. We found a weak association between use of oral bisphosph …
The purpose of this study was to evaluate the association between the use of bisphosphonates and the risk of developing renal cell ca …
Vascular calcification and arterial stiffness in chronic kidney disease: implications and management.
Toussaint ND, Kerr PG. Toussaint ND, et al. Nephrology (Carlton). 2007 Oct;12(5):500-9. doi: 10.1111/j.1440-1797.2007.00823.x. Nephrology (Carlton). 2007. PMID: 17803475 Review.
Cardiovascular (CV) disease is the commonest cause of mortality in patients with chronic kidney disease (CKD). Vascular calcification (VC), induced by calcium and phosphate excess and uraemia, is a major risk factor and is independently associated with CV events and …
Cardiovascular (CV) disease is the commonest cause of mortality in patients with chronic kidney disease (CKD). Vascular calcification …
Zoledronic acid and ibandronate-induced nephrotoxicity in 2D and 3D proximal tubule cells derived from human and rat.
Valencia LJ, Tseng M, Chu ML, Yu L, Adedeji AO, Kiyota T. Valencia LJ, et al. Toxicol Sci. 2024 Feb 28;198(1):86-100. doi: 10.1093/toxsci/kfad123. Toxicol Sci. 2024. PMID: 38059598
Drug-induced proximal tubule (PT) injury remains a serious safety concern throughout drug development. ...Furthermore, ibandronate-exposed hRPTEC/TERT1s and rPPTECs produced higher levels of inflammatory and kidney injury biomarkers compared to zoledronic acid, indi …
Drug-induced proximal tubule (PT) injury remains a serious safety concern throughout drug development. ...Furthermore, ibandronate-ex …
Spontaneous fracture: multiple causes.
Wick JY. Wick JY. Consult Pharm. 2009 Feb;24(2):100-2, 105-8, 110-2. doi: 10.4140/tcp.n.2009.100. Consult Pharm. 2009. PMID: 19275452 Review.
Among the most common causes of spontaneous fracture are osteoporosis (calcium deficiency and corticosteroid-induced), malignancy, overexposure to vitamin A, periprosthetic weakening, Brucellosis, cerebral palsy (especially in children), and osteodystrophy because of chron …
Among the most common causes of spontaneous fracture are osteoporosis (calcium deficiency and corticosteroid-induced), malignancy, ov …
60 results